Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Present aspects and future developments with ACE inhibitors.

J L Reid1

  • 1Department of Materia Medica, University of Glasgow, UK.

Cardiology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.

Hypertension (Dallas, Tex. : 1979)·1995
Same author

Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.

Arteriosclerosis, thrombosis, and vascular biology·1995
Same author

Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.

Journal of human hypertension·1995
Same author

Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

Annals of the New York Academy of Sciences·1995
Same author

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.

Journal of human hypertension·1995
Same author

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.

Journal of cardiovascular pharmacology·1995
Same journal

Aortic Valve Sclerosis: More Than an Incidental Echocardiographic Finding.

Cardiology·2026
Same journal

Can resting segmental strain identify obstructive coronary artery disease in chronic coronary syndrome patients referred to CABG?

Cardiology·2026
Same journal

Mortality Impact of Stroke and Major Bleeding Across the Ejection Fraction Spectrum in Patients Hospitalized for Acute Heart Failure With Prevalent Atrial Fibrillation.

Cardiology·2026
Same journal

Impact of Inflammatory Disorders on Outcomes in Acute Heart Failure: A Nationwide Analysis.

Cardiology·2026
Same journal

Predictors and Clinical Impact of Tricuspid Regurgitation After Pericardiectomy for Constrictive Pericarditis.

Cardiology·2026
Same journal

Utilization of Guideline-Directed Medical Therapies and Transcatheter-Edge-to-Edge Repair in Patients with Significant Secondary Mitral Regurgitation.

Cardiology·2026
See all related articles

Angiotensin-converting enzyme (ACE) inhibitors effectively treat hypertension without causing rapid heart rate. These drugs are beneficial for elderly patients and those with heart failure, expanding their clinical utility.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Several angiotensin-converting enzyme (ACE) inhibitors are in clinical use for hypertension.
  • Numerous ACE inhibitors are currently under development, indicating expanding applications.

Purpose of the Study:

  • To review the expanded clinical applications of ACE inhibitors.
  • To discuss the efficacy of ACE inhibitors in specific patient populations.

Main Methods:

  • Literature review of current clinical use and development of ACE inhibitors.
  • Analysis of clinical outcomes in patients treated with ACE inhibitors.

Main Results:

  • ACE inhibitors lower blood pressure without inducing tachycardia.
  • ACE inhibitors are effective in treating hypertension in the elderly and patients with heart failure.

Related Experiment Videos

  • Plasma renin assay utility in determining optimal dosage is limited.

    • Conclusions:

    • ACE inhibitors offer significant benefits in hypertension management, particularly in elderly and heart failure patients.
    • Further research into tissue-specific ACE inhibitors may yield valuable clinical advancements.